Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

Cancer Research

Volumn 71, Issue 18, 2011, Pages 6019-6029

  Darshan, Medha S ^a   Loftus, Matthew S ^a   Thadani Mulero, Maria ^a   Levy, Benjamin P ^a   Escuin, Daniel ^c   Zhou, Xi Kathy ^a,b   Gjyrezi, Ada ^a   Chanel Vos, Chantal ^a   Shen, Ruoqian ^a   Tagawa, Scott T ^a,b   Bander, Neil H ^a,b   Nanus, David M ^a,b   Giannakakou, Paraskevi ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Weill Cornel Medical College   (United States)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA TUBULIN; DOCETAXEL; DYNEIN ADENOSINE TRIPHOSPHATASE; METRIBOLONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOACCUMULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL ISOLATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DRUG RESPONSE; GENE ACTIVATION; HUMAN; HUMAN CELL; METASTASIS; MICROTUBULE; MUTATION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; DYNEINS; FEMALE; HUMANS; MALE; MICROTUBULES; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 80052808323     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1417     Document Type: Article

References (48)

1. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. (Pubitemid 33741879)
2. Petrylak DP. New paradigms for advanced prostate cancer. Rev Urol 2007;9 Suppl 2:S3-12.
3. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15. (Pubitemid 34728896)
4. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9. (Pubitemid 38524696)
5. Attard G, Richards J, de Bono JS. Targeting the androgen receptor signaling pathway in metastatic prostate cancer. Clin Cancer Res 2011;17:1649-57.
6. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-109. (Pubitemid 23049638)
7. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
8. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
9. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20. (Pubitemid 39315318)
10. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65. (Pubitemid 38525281)
11. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971;28:1479-99.
12. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-80.
13. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008;14:111-22.
14. Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T, et al. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2000;2:709-17.
15. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75. (Pubitemid 38340305)
16. Carbonaro M, O'Brate A, Giannakakou P. Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. J Cell Biol 2011;192:83-99.
17. Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV, et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A 2002;99:10855-60.
18. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH, et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009;69:1579-85.
19. Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009;69:8386-94.
20. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010;70:7992-8002.
21. Brass AL, Barnard J, Patai BL, Salvi D, Rukstalis DB. Androgen upregulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res 1995;55:3197-203.
22. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, et al. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 2000;141:1699-704. (Pubitemid 32274399)
23. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A, et al. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993;53:1304-11. (Pubitemid 23097107)
24. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58:4055-60. (Pubitemid 28440554)
25. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-34. (Pubitemid 27381196)
26. Ding D, Xu L, Menon M, Reddy GP, Barrack ER. Effect of a short CAG (glutamine) repeat on human androgen receptor function. Prostate 2004;58:23-32. (Pubitemid 38057985)
27. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25. (Pubitemid 27289821)
28. Burkhardt JK, Echeverri CJ, Nilsson T, Vallee RB. Overexpression of the dynamitin (p50) subunit of the dynactin complex disrupts dynein-dependent maintenance of membrane organelle distribution. J Cell Biol 1997;139:469-84.
29. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920-8. (Pubitemid 46340368)
30. Schall R. Estimation in generalized linear-models with random effects. Biometrika 1991;78:719-27.
31. Breslow NE, Clayton DG. Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993;88:9-25.
32. Wolfinger R, Oconnell M. Generalized linear mixed models - a pseudo-likelihood approach. J Stat Comput Simul 1993;48:233-243.
33. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
34. Ross JL, Ali MY, Warshaw DM. Cargo transport: molecular motors navigate a complex cytoskeleton. Curr Opin Cell Biol 2008;20:41-7.
35. Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696-701. (Pubitemid 46560805)
36. Wang X, Yin L, Rao P, Stein R, Harsch KM, Lee Z, et al. Targeted treatment of prostate cancer. J Cell Biochem 2007;102:571-9. (Pubitemid 47557412)
37. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007;25:3965-70. (Pubitemid 47477275)
38. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516-21. (Pubitemid 43898814)
39. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011;8:244-50.
40. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 2000;97:2904-9. (Pubitemid 30159270)
41. Giannakakou P, Snyder JP. Resistance to microtubule-targeting drugs. In: Fojo T, editor. The role of microtubules in cell biology, neurobiology, and oncology. Totowa, NJ: Humana Press; 2008. p. 357-94.
42. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH, et al. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science 2004;305:866-9. (Pubitemid 39038421)
43. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-9. (Pubitemid 46649868)
44. Attard G, Reid AH, Olmos D, de Bono JS. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69:2912-8.
45. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010;2:25ra23.
46. Grad JM, Dai JL, Wu S, Burnstein KL. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol Endocrinol 1999;13:1896-911. (Pubitemid 30645263)
47. Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5:610-20.
48. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.